VAIA
ANIK icon

Virtus Alternative Investment Advisers’s Anika Therapeutics ANIK Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-152
Closed -$8K – 234
2019
Q4 		$8K Buy
+152
New +$8.83K 0.12% 224

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Virtus Alternative Investment Advisers's ANIK Position: Q1 2020 in Review

Virtus Alternative Investment Advisers sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 152 shares — an estimated $8K sold.

Virtus Alternative Investment Advisers first reported a position in ANIK in Q4 2019 and held it in 1 quarter. The position peaked at $8K in Q4 2019. 164 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Virtus Alternative Investment Advisers reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 152 Anika Therapeutics shares in Q1 2020, an estimated $8K.
  • Virtus Alternative Investment Advisers first reported a position in Anika Therapeutics in Q4 2019 and held it in 1 quarter.
  • Virtus Alternative Investment Advisers's Anika Therapeutics position peaked at $8K in Q4 2019.
  • 164 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2020, filed 15 May 2020.